Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials

REFERENCES

• American Psychiatric Association. Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (4th ed.). Washington, DC: American Psychiatric Association, 2000.
   Google Scholar
• Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340(19):1482–1490.
   PubMed Web of Science ®Google Scholar
• Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91(12):1773–1796.
   PubMed Web of Science ®Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonist for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867.
   PubMed Web of Science ®Google Scholar
• Anton RE, O’Malley SS, Ciraulo RA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson MF, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 2006; 295(17):2003–2017.
   PubMed Web of Science ®Google Scholar
• Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient. Drugs 1998; 56(4):571–585.
   PubMed Web of Science ®Google Scholar
• Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 2011; 72(6):1012–1018.
   Google Scholar
• Litten RZ, Allen JP. Advances in development of medications for alcoholism treatment. Psychopharmacology (Berl) 1998; 139(1–2):20–33.
   Google Scholar
• Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SM, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence specific effect on heavy drinking. J Clin Psychopharmacol 2006; 26(6):610–625.
   PubMed Web of Science ®Google Scholar
• Roozen HG, de Waart R, van der Windt DAWM, van den Brink W, de Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of naltrexone in the maintenancetreatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 2006; 16(5):311–323.
   PubMed Web of Science ®Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867
   PubMed Web of Science ®Google Scholar
• Rösner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22(1):11–23.
   Google Scholar
• Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811–828.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2009.
   Google Scholar
• Agencja Oceny Technologii Medycznych. Wytyczne Przeprowadzania Oceny Technologii Medycznych (HTA). Kraków-Warszawa, 2009.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1):1–12.
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
   PubMed Web of Science ®Google Scholar
• Peacock P, Peacock J. Oxford Handbook of Medical Statistics. Oxford University Press, 2010.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington DC: American Psychiatric Association, 1994; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed.). Washington DC: American Psychiatric Association, 1987.
   Google Scholar
• Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35(6):587–593.
   PubMed Web of Science ®Google Scholar
• Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22(6):592–598.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49(11):876–880.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54(8):737–742.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Clay KL, Watson NT, O’Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56(Suppl 7):39–44.
   PubMed Web of Science ®Google Scholar
• Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156(11):1758–1764.
   PubMed Web of Science ®Google Scholar
• Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001; 21(1):72–77.
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101(10):1451–1462.
   PubMed Web of Science ®Google Scholar
• Huang M-C, Chen C-H, Yu J-M, Chen C-C. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol 2005; 10(3):289–292.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345(24):1734–1739.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R, Kirk G, Krol W, Krystal J. Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6(5):566–573.
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Ahmadi N. A double blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. Ger J Psychiatr 2002; 5(4):85–89.
   Google Scholar
• Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103(12):2035–2044.
   Google Scholar
• O’Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin and Exp Res 2008; 32(7):1271–1283.
   PubMed Web of Science ®Google Scholar
• Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005; 25(4):349–357.
   PubMed Web of Science ®Google Scholar
• Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26(9):1381–1387.
   Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60(1):92–99.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Holzbach R, Briken P, Stracke R, Wiedemann K. The NALCAM-study: efficacy, tolerability, outcome. Sucht 2003; 49:342–351.
   Google Scholar
• Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176(11):530–534.
   PubMed Web of Science ®Google Scholar
• Morris PLP, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96(11):1565–1573.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49(11):881–887.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53(3):217–224.
   PubMed Web of Science ®Google Scholar
• Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson L-H, Stolt G, Willander A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27(7):1142–1149.
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Babaeebeigi M, Maany I, Porter J, Mohagheghzadeh M, Ahmadi N, Dehbozorgi G. Naltrexone for alcohol-dependent patients. Ir J Med Sci 2004; 173(1):34–37.
   Google Scholar
• Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36(6):544–552.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25(9):1335–1341.
   PubMed Web of Science ®Google Scholar
• Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2008; 34(4):449–461.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Opioid antagonist for alcohol dependence. Cochrane Database Syst Rev 2002; 2:CD001867.
   Google Scholar
• Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O’Malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 2007; 61(11):1290–1295.
   Google Scholar
• Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R, VA CSP No. 425 Study Team. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, “Naltrexone in the treatment of alcoholism”. Alcohol Clin Exp Res 2008; 32(1):85–91.
   Google Scholar
• Rubio G, Jimenez-Arriero MA, Ponce G, Palomo. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36(5):419–425.
   PubMed Web of Science ®Google Scholar